Subscribe Sign In Register

Premium

How ValueAct Shook Off Its Big Loss from Valeant

The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.

By Stephen Taub Stephen Taub
January 6, 2017
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg

Ron Antonelli/Bloomberg

Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Pharmaceutical Valueact Jeff Ubben Valiant
Related
Art_Soleus_1130 (1).jpg
Premium
Soleus Goes Activist
Stephen Taub
November 30, 2023
Art_BiophmarmaIPO_1129.jpg
Premium
Hedge Funds Eye Next Biopharma IPO
Stephen Taub
November 29, 2023
Cattle Supply
Sponsored
Why Cattle Remain in Short Supply